Prestige Biopharma said Wednesday that the dosing of its Avastin biosimilar, HD204, conducted by global contract research organization (CRO) IQVIA, will be completed this month.HD204 is being studied in a global phase 3 clinical trial by two leading CROs, enrolling 650 patients in 17 countries world
Celltrion said that Rani Therapeutics has reported positive topline results from its phase 1 clinical trial of RT-111, an oral form of ustekinumab.The trial, conducted in Australia, involved 55 healthy adults and aimed to evaluate the pharmacokinetics (PK) and safety of RT-111, showcasing an impress
Medipost has voluntarily withdrawn its phase 2 clinical trial of Cartistem in Japan. The company said it did so to focus on a separate phase 3 monotherapy study.In a public disclosure Friday, Medipost said it has received approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) f
The government and the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those considered for human cell management business licenses.The National Assembly passed the “Amendment to the Act on Safety and Support for Advanced Regenera
Samsung Bioepis and Samil Pharmaceutical have announced a marketing partnership for the local sales of SB15, a biosimilar referencing Eylea.Eylea is a blockbuster ophthalmic drug developed by Regeneron and treats wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), which can
Biotech and healthcare companies operating in the new technology industry face limitations in investing and raising funds to increase corporate value due to their small size, burdened with “initial investment costs” and “lack of specialized manpower.”Therefore, the government should provide institut
Bridge Biotherapeutics said Tuesday that the Independent Data Monitoring Committee (IDMC) has recommended the company continue conducting phase 2 clinical trial of BBT-877, its candidate for treating idiopathic pulmonary fibrosis (IPF).According to the company, the IDMC was held to review the safety
CHA Biotech, a Kosdaq-listed cell therapy company, said Monday that it has signed an agreement with Cancure, a U.S. immunotherapy developer, for a joint development of natural killer (NK) cell treatment to increase the anti-cancer effect of NK cell therapeutics.Under the agreement, CHA Biotech will
Samsung Bioepis, a subsidiary of Samsung Biologics, has surpassed 1 trillion won ($748.5 million) in annual sales since it was founded 12 years ago.According to the 2023 earnings report released by the company on Wednesday, Samsung Bioepis posted annualized sales of 1.02 trillion won and operating i
CHA Vaccine Institute, a Kosdaq-listed vaccine development company, said Thursday that it has developed Lipoplex, a messenger ribonucleic acid (mRNA) delivery system using adjuvants.Medicines utilizing mRNA have gained prominence since the Covid-19 pandemic. The advantage of mRNA vaccines and therap
NKMAX's stock price has plummeted overnight, raising questions in the market. However, the company hurriedly tried to calm down the jitters, saying there were “no internal issues.”On Wednesday morning, NKMAX’s stock price fell by 29.87 percent, or 1,550 won ($1.15), to 3,640 won from the previous da
AriBio has entered into a comprehensive collaboration with Vietnam's state-owned Central Pharmaceutical Joint Stock Company (CPC1) to sell and distribute AR1001, an oral dementia treatment candidate.The Korean company said Wednesday that it would also collaborate with OPC Pharma on developing natura
Deep Bio, an AI-based medical solutions provider, said Tuesday that it has appointed Lee Soo-hyun, a former accountant at Samil PwC with experience in many IPOs, as its new chief finance officer.New CFO Lee will oversee the investment, technology special listing, and growth strategy at Deep Bio. The
Samsung Biologics and Celltrion ranked among the top 25 biotech companies worldwide.Genetic Engineering & Biotechnology News (GEN), a U.S. biotech and health publication, recently announced the "2024 Biotech Top 25" based on the analysis of market capitalization (as of Dec. 8, 2023) of biotech compa
Samsung Bioepis, a subsidiary of Samsung Biologics, said it has received product approval from the Ministry of Food and Drug Safety for Epiruscly, a biosimilar referencing Soliris, last Friday.Soliris, developed by AstraZeneca's subsidiary Alexion Pharmaceuticals, is a high-cost biopharmaceutical fo
Lotte Biologics said it has entered into a strategic partnership with NJ Bio, a U.S. contract research organization (CRO), to enhance antibody-drug conjugate (ADC) services.Established in 2018 and based in New Jersey, NJ Bio specializes in integrated chemical and biological services for linker paylo
EONE-Diagnomics Genome Center (EDGC), a Kosdaq-listed genomic analysis company, said Friday that its clinical testing laboratory in Incheon had obtained the Clinical Laboratory Improvement Amendments (CLIA) certification in the U.S.CLIA is a U.S. standard certification system that verifies the accur
Genome & Company has declared its strategic move to penetrate the third-line treatment market for gastric cancer through the development of a microbiome-based immunotherapy. At an online news conference Friday, Genome & Company unveiled the phase 2 clinical trial results of its candidate, GEN-001, f
CG Bio, a regenerative medicine company, said Thursday that it has signed a business agreement with the Research Center for Marine-integrated Biomedical Technology (MiBC) at Pukyong National University (PKNU) and the Korea Institute of Ocean Science & Technology (KIOST) to develop medical ingredient
Onconic Therapeutics, a new drug developer affiliated with Jeil Pharmaceutical, has passed the technical evaluation and will begin the listing process on the Kosdaq market in earnest.Market insiders see whether the company can strengthen its R&D capabilities by raising funds through the listing.Onco